SciClone Appoints Nancy T. Chang, Ph.D., to Its Board of Directors
FOSTER CITY, CA -- (Marketwired) -- 09/23/13 -- SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Nancy T.
Chang, Ph.D., has been appointed a member of the Company's board of
directors. Dr. Chang has more than 30 years of experience in the
pharmaceutical and biotechnology industry, and has successfully
developed and commercialized multiple therapeutic and diagnostic
products. She is highly respected as an innovative and successful
executive and director, entrepreneur, strategic advisor, investor and
philanthropist. Dr. Chang received widespread acclaim for the
founding and subsequent sale of Tanox to Genentech in 2007, and for
changing the treatment paradigm for allergy-related asthma through
the successful development and commercialization of Xolair(R).
Friedhelm Blobel, Ph.D., Chief Executive Officer, joined Jon S. Saxe,
Chairman, in welcoming Dr. Chang to SciClone's board of directors.
"Nancy brings an extraordinary range of complementary business
experience to SciClone's board, including a deep understanding of the
global pharmaceutical marketplace, including the China market, and
extensive company management, board participation, healthcare
strategy and policy expertise," said Dr. Blobel. "As SciClone
continues to work to solidify its reputation as one of the top
echelon specialty pharmaceutical companies in the China market, and
implements commercial and partnering programs designed to grow
revenue and profitability, Nancy's strategic advisory will be
"I believe that SciClone is well-positioned to take advantage of the
growth opportunities in the expanding China pharmaceuticals market,
and to continue to build its reputation and success as company
committed to commercializing high quality, differentiated
therapeutics," said Dr. Chang. "I look forward to working with the
dedicated management team and board of directors to help the Company
reach its next level of achievement."
For more than 20 years, Dr. Chang served as the Co-founder,
President, CEO and Chairman of Tanox, which was sold to Genentech in
2007. Today, Dr. Chang serves as the President of Apex Enterprises,
Inc., an investment management company with a major focus on
healthcare investments. Previously, she was the Chairperson and
Senior Managing Director of Caduceus Asia Partners at OrbiMed
Advisors L.L.C. Prior to founding Tanox, Dr. Chang held several
leadership positions at Centocor, now a division of Johnson and
Johnson. She was also an Associate Professor at Baylor College of
Medicine, and before that, she worked at the Roche Institute of
Molecular Biology. She has served on the boards of a number of
companies, including Charles River Laboratories International, Inc.,
Applied Optoelectronics Inc. and others. More recently, she joined
the board of directors of Ansun, a San Diego-based biotech company.
In addition, Dr. Chang was a member of the board of directors at the
Biotechnology Industry Organization (BIO) and BioHouston. Dr. Chang
also was a Director at the Federal Reserve Bank in the Dallas Houston
Branch, and was a Director for Project Hope. Dr. Chang was inducted
into the Texas Science Hall of Fame in 2001 for exemplary achievement
in science and is the recipient of many awards, such as the Associate
of Women in Computing: Top 20 Houston Women in Technology, Who's Who
National Registry, and Houston Entrepreneur of the Year (sponsored by
Ernst & Young, Inc. Magazine and Merrill Lynch). She has published
more than 35 papers on topics ranging from monoclonal antibodies to
HIV and holds seven patents. Dr. Chang received her Doctorate in
Biological Chemistry from Harvard University.
SciClone Pharmaceuticals is a revenue-generating, specialty
pharmaceutical company with a substantial commercial business in
China and a product portfolio of therapies for oncology, infectious
diseases and cardiovascular, urological, respiratory, and central
nervous system disorders. SciClone's proprietary lead product,
ZADAXIN(R) (thymalfasin), is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Through its promotion business with
pharmaceutical partners, SciClone markets multiple branded products
in China which are therapeutically differentiated. The Company has
successfully in-licensed products with the potential to become future
market leaders and to drive the Company's long-term growth. SciClone
is a publicly-held corporation based in Foster City, California, and
trades on the NASDAQ Global Select Market under the symbol SCLN. For
additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. Please also refer to other
risks and uncertainties described in SciClone's filings with the SEC.
All forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
Wilson W. Cheung
Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.